RecruitingInterventional · Not applicableNCT04101669 ↗A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity
Active, not recruitingInterventional · Phase 3NCT05869903 ↗A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)Alpana P. ShuklaPIInterventionDrug: Orforglipron · Drug: PlaceboDatesJun 2023 – Jul 2025· Results postedSponsorEli Lilly and CompanyObesityOverweightOverweight or Obesity
RecruitingInterventional · Not applicableNCT06335810 ↗Reducing Obesity Using Social Ties (ROBUST): Randomized Control TrialErica PhillipsPIInterventionBehavioral: Social Network Intervention · Behavioral: Individual Lifestyle Intervention · Other: Social Network MemberDatesApr 2024 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityObesity
Active, not recruitingInterventional · Phase 2NCT06577090 ↗A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or ObeseLouis J AronnePIInterventionBiological: Nimacimab injection · Biological: Nimacimab placebo injection · Combination product: semaglutide injection · Biological: Nimacimab 300 mg injectionDatesAug 2024 – Nov 2026 (est.)SponsorSkye Bioscience INCObesity
RecruitingInterventional · Not applicableNCT06724172 ↗CHIME: Comparing Health Interventions for Maternal EquityDaniel W SkupskiPIInterventionBehavioral: Self-Management · Behavioral: Community-BasedDatesJan 2026 – Jan 2030 (est.)SponsorStanford UniversityObesity and OverweightNutritionChronic Disease+2 more
RecruitingInterventional · Not applicableNCT07090005 ↗Comparing the Efficacy and Safety of the EndoZipTM System and Apollo Endoscopic Sleeve Gastroplasty (ESG), Followed by Behavioral Modifications, in Obese Patients Who Have Not Achieved Weight Reduction Through Non-surgical Methods.Reem Z. SharaihaPIInterventionDevice: EndoZip System · Device: OverStitch Endoscopic Suturing System (ESG)DatesNov 2025 – Jun 2027 (est.)SponsorNitinotes Surgical Ltd.ObesityOverweight
RecruitingInterventional · Phase 4NCT07257484 ↗Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsSarah SchmitzPIInterventionDrug: TirzepatideDatesJun 2026 – Dec 2027 (est.)SponsorWeill Medical College of Cornell UniversityObesity (Disorder)Breast Cancer
Active, not recruitingInterventional · Phase 3NCT07357415 ↗A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind TrialAlpana P. ShuklaPIInterventionDrug: RetatrutideDatesJan 2026 – Oct 2028 (est.)SponsorEli Lilly and CompanyObesityOverweight
RecruitingInterventional · Phase 3NCT07392190 ↗A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 DiabetesLouis J AronnePIInterventionDrug: Eloralintide · Drug: PlaceboDatesFeb 2026 – Jun 2028 (est.)SponsorEli Lilly and CompanyOverweightObesity
RecruitingInterventional · Phase 3NCT07571005 ↗Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)Ana C. KriegerPIInterventionDrug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)DatesMay 2026 – Jul 2028 (est.)SponsorNovo Nordisk Pharmaceuticals, Inc.ObesityOverweightObstructive Sleep Apnoea
RecruitingInterventional · Phase 3NCT07571109 ↗Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)Ana C. KriegerPIInterventionDrug: NNC0487-0111 · Drug: Placebo (matched to NNC0487-0111)DatesMay 2026 – Jun 2028 (est.)SponsorNovo Nordisk Pharmaceuticals, Inc.ObesityOverweightObstructive Sleep Apnoea
RecruitingInterventional · Phase 3NCT07595549 ↗A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)Alpana P. ShuklaPIInterventionDrug: PF-08653944 · Other: PlaceboDatesJun 2026 – May 2028 (est.)SponsorPfizer, Inc.ObesityOverweight and/or ObesityOverweight
RecruitingInterventional · Phase 3NCT07720271 ↗Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)Alpana P. ShuklaPIInterventionDrug: zenagamtide · Drug: PlaceboDatesAug 2026 – Jun 2028 (est.)SponsorNovo Nordisk Pharmaceuticals, Inc.OverweightObesity
CompletedInterventional · Phase 3NCT04184622 ↗Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)Louis J AronnePIInterventionDrug: Tirzepatide · Drug: PlaceboDatesDec 2019 – Apr 2022· Results postedSponsorLilly USA, LLCOverweightObesity
CompletedInterventional · Phase 3NCT04660643 ↗Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)Louis J AronnePIInterventionDrug: Tirzepatide · Other: PlaceboDatesMar 2021 – Apr 2023· Results postedSponsorEli Lilly and CompanyObesityOverweight
CompletedInterventional · Phase 3NCT04788511 ↗Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection FractionParag GoyalPIInterventionDrug: Semaglutide · Drug: Placebo (semaglutide)DatesMar 2021 – Apr 2023· Results postedSponsorNovo Nordisk Pharmaceuticals, Inc.Obesity
CompletedInterventional · Phase 2NCT05295875 ↗A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)Louis J AronnePIInterventionDrug: ALT-801 · Other: PlaceboDatesMar 2022 – Sep 2023SponsorAltimmune, Inc.Obesity/Overweight
CompletedInterventional · Phase 3NCT05394519 ↗Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesAlpana P. ShuklaPIInterventionDrug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutideDatesFeb 2023 – Jan 2025SponsorNovo Nordisk Pharmaceuticals, Inc.OverweightObesityType 2 Diabetes Mellitus
CompletedInterventional · Not applicableNCT05396443 ↗A Telehealth Lifestyle Intervention for Black Adolescent Girls at Risk for Type 2 Diabetes: A Pilot StudyTashara Marie LeakPIInterventionBehavioral: Black Girls for Wellness TelehealthDatesAug 2022 – Feb 2025SponsorWeill Medical College of Cornell UniversityObesity, ChildhoodType2Diabetes
CompletedInterventional · Phase 2NCT05616013 ↗A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and WomenLouis J AronnePIInterventionBiological: Bimagrumab · Drug: Semaglutide · Other: PlaceboDatesNov 2022 – May 2024· Results postedSponsorVersanis BioObesityObeseOverweight or Obesity